相似文献
1
Kidney Cancer Research Highlights from ASCO-GU 2024 Meeting.2024年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会的肾癌研究亮点
Kidney Cancer J. 2024 Mar;22(1):28-32.
2
Inside the 2015 ASCO Genitourinary Cancers Symposium.2015年美国临床肿瘤学会泌尿生殖系统癌症研讨会现场
Future Oncol. 2015;11(13):1859-62. doi: 10.2217/fon.15.103.
3
Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium.去势抵抗性前列腺癌的新型药物与临床试验：2023年美国临床肿瘤学会-泌尿生殖系统癌症研讨会的最新进展
Exp Hematol Oncol. 2023 Aug 1;12(1):68. doi: 10.1186/s40164-023-00430-1.
4
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 1 - kidney cancer.2016 年美国临床肿瘤学会泌尿生殖系统癌症研讨会内部资料：第 1 部分 - 肾癌。
Future Oncol. 2016 Sep;12(17):1967-70. doi: 10.2217/fon-2016-0102. Epub 2016 Jun 17.
5
Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.2016 年美国临床肿瘤学会泌尿生殖系统癌症研讨会内部资料：第 2 部分——前列腺癌和膀胱癌。
Future Oncol. 2016 Sep;12(17):1971-4. doi: 10.2217/fon-2016-0166. Epub 2016 Jun 17.
6
2023 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium Meeting highlights.2023年美国临床肿瘤学会泌尿生殖系统（ASCO-GU）癌症研讨会会议亮点。
Can Urol Assoc J. 2023 May;17(5):E144-E151. doi: 10.5489/cuaj.8374.
7
2024 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium Meeting highlights.2024年美国临床肿瘤学会泌尿生殖系统（ASCO-GU）癌症研讨会会议亮点。
Can Urol Assoc J. 2024 May;18(5):E179-E186. doi: 10.5489/cuaj.8797.
8
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.新型抗体偶联药物和联合疗法在尿路上皮癌中的应用：2023 年 ASCO-GU 癌症研讨会最新进展。
J Hematol Oncol. 2023 Jul 28;16(1):85. doi: 10.1186/s13045-023-01475-9.
9
2023 ASCO Genitourinary Cancers Symposium: a focus on urothelial carcinoma.2023年美国临床肿瘤学会泌尿生殖系统癌症研讨会：聚焦尿路上皮癌。
Expert Rev Anticancer Ther. 2023 Jul-Dec;23(11):1123-1126. doi: 10.1080/14737140.2023.2265570. Epub 2023 Oct 27.
10
2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma.2023 年 ASCO 泌尿生殖系统癌症研讨会：聚焦肾细胞癌。
Expert Rev Anticancer Ther. 2023 Jul;23(7):669-672. doi: 10.1080/14737140.2023.2218091. Epub 2023 May 29.
本文引用的文献
1
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.辅助纳武利尤单抗用于肾切除术后高复发风险的局限性肾细胞癌：随机、安慰剂对照、III期CheckMate 914试验的B部分
J Clin Oncol. 2025 Jan 10;43(2):189-200. doi: 10.1200/JCO.24.00773. Epub 2024 Sep 20.
2
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial.纳武利尤单抗联合伊匹单抗辅助治疗肾切除术后局部肾细胞癌（CheckMate 914）：一项双盲、随机、III 期临床试验。
Lancet. 2023 Mar 11;401(10379):821-832. doi: 10.1016/S0140-6736(22)02574-0. Epub 2023 Feb 9.
3
Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade.肾细胞癌的辅助治疗选择 - 靶向转移级联。
Nat Rev Urol. 2023 Mar;20(3):179-193. doi: 10.1038/s41585-022-00666-2. Epub 2022 Nov 11.
4
Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.卡博替尼联合纳武利尤单抗治疗非透明细胞肾细胞癌患者的 II 期临床试验及基因组相关性分析。
J Clin Oncol. 2022 Jul 20;40(21):2333-2341. doi: 10.1200/JCO.21.01944. Epub 2022 Mar 17.
5
Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.寡进展性转移性肾细胞癌立体定向消融放疗的 II 期临床试验。
Eur Urol Oncol. 2022 Apr;5(2):216-224. doi: 10.1016/j.euo.2021.12.001. Epub 2022 Jan 2.
6
Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.寡转移肾细胞癌的立体定向放疗和短期帕博利珠单抗治疗：RAPPORT 试验。
Eur Urol. 2022 Apr;81(4):364-372. doi: 10.1016/j.eururo.2021.12.006. Epub 2021 Dec 23.
7
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.贝伐珠单抗治疗 von Hippel-Lindau 病相关肾细胞癌
N Engl J Med. 2021 Nov 25;385(22):2036-2046. doi: 10.1056/NEJMoa2103425.
8
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.卡博替尼联合阿替利珠单抗治疗晚期肾细胞癌：来自 COSMIC-021 研究的结果。
J Clin Oncol. 2021 Nov 20;39(33):3725-3736. doi: 10.1200/JCO.21.00939. Epub 2021 Sep 7.
9
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.肾细胞癌肾切除术后辅助帕博利珠单抗。
N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391.
10
Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I.肾脏肿块和局限性肾细胞癌：评估、管理和随访：AUA 指南：第 1 部分。
J Urol. 2021 Aug;206(2):199-208. doi: 10.1097/JU.0000000000001911. Epub 2021 Jul 11.
Zotero 插件